Real-world effects of anti-vascular endothelial growth factor injection frequency on visual outcomes in patients with diabetic macular oedema.
Carter J PayneUrvi GuptaChristopher M MaatoukBlanche L KuoScott W PerkinsRishi P SinghKatherine E TalcottPublished in: Eye (London, England) (2024)
Many patients experienced improvements in BVA and CST over 12 months of treatment despite receiving less frequent anti-VEGF therapy than recommended in the pivotal trials. The present study showed that extended treatment intervals with bevacizumab were effective in preserving vision of many individuals with high baseline BVA.
Keyphrases
- vascular endothelial growth factor
- end stage renal disease
- endothelial cells
- ejection fraction
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- stem cells
- insulin resistance
- skeletal muscle
- metabolic syndrome
- combination therapy
- replacement therapy
- patient reported outcomes
- wound healing
- weight loss
- smoking cessation
- cataract surgery